Compare CCD & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCD | ACHV |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 662.0M | 726.5M |
| IPO Year | 2014 | 2018 |
| Metric | CCD | ACHV |
|---|---|---|
| Price | $22.41 | $7.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | 55.2K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 10.61% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.99 | $2.62 |
| 52 Week High | $26.99 | $8.64 |
| Indicator | CCD | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 29.99 | 48.49 |
| Support Level | $21.70 | $7.01 |
| Resistance Level | $22.99 | $8.63 |
| Average True Range (ATR) | 0.50 | 0.37 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 7.92 | 40.43 |
Calamos Dynamic Convertible and Income Fund operates as a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It predominantly invests in a portfolio of convertible securities, investment grade and below investment grade bonds, loans, equity-linked notes, and floating rate securities.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.